Is BioNTech SE (BNTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 65.9% / 30% | 6.0% / 30% | 15.91% / 5% | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 65.9% / 33% | 6.0% / 33% | 15.91% / 5% | ✗ NOT HALAL |
| MSCI | 1.1% / 33% | 74.5% / 33% | 6.8% / 33% | 15.91% / 5% | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 65.9% / 33% | 6.0% / 33% | 15.91% / 5% | ✗ NOT HALAL |
| FTSE | 1.1% / 33% | 74.5% / 33% | 6.8% / 50% | 15.91% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 78.7% | |
| Operating Margin | -33.3% | |
| Net Margin | -39.6% | |
| Return on Equity (ROE) | -5.9% | |
| Return on Assets (ROA) | -3.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $456M |
| Free Cash Flow | -$293M |
| Total Debt | $267M |
| Debt-to-Equity | 1.4 |
| Current Ratio | 7.5 |
| Total Assets | $22.0B |
Price & Trading
| Last Close | $87.46 |
| 50-Day MA | $103.71 |
| 200-Day MA | $103.78 |
| Avg Volume | 1.2M |
| Beta | 1.5 |
|
52-Week Range
$79.52
| |
About BioNTech SE (BNTX)
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioNTech SE (BNTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioNTech SE is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioNTech SE's debt ratio?
BioNTech SE's debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are BioNTech SE's key financial metrics?
BioNTech SE has a market capitalization of $21.5B, and revenue of $2.9B. The company maintains a gross margin of 78.7% and a net margin of -39.6%. Return on equity stands at -5.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.